EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing.
from The Medical News http://ift.tt/1FfVPHr
from The Medical News http://ift.tt/1FfVPHr
No comments:
Post a Comment